DE602006015050D1 - Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür - Google Patents

Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Info

Publication number
DE602006015050D1
DE602006015050D1 DE602006015050T DE602006015050T DE602006015050D1 DE 602006015050 D1 DE602006015050 D1 DE 602006015050D1 DE 602006015050 T DE602006015050 T DE 602006015050T DE 602006015050 T DE602006015050 T DE 602006015050T DE 602006015050 D1 DE602006015050 D1 DE 602006015050D1
Authority
DE
Germany
Prior art keywords
hybrid molecules
tat
hiv
polypeptides
hiv hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015050T
Other languages
English (en)
Inventor
Susan Barnett
Rino Rappuoli
Victoria Sharma
Indresh Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE602006015050D1 publication Critical patent/DE602006015050D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602006015050T 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür Active DE602006015050D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65063505P 2005-02-03 2005-02-03
PCT/US2006/003935 WO2006084179A2 (en) 2005-02-03 2006-02-03 Hiv tat-cd4 hybried molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602006015050D1 true DE602006015050D1 (de) 2010-08-05

Family

ID=36777987

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015050T Active DE602006015050D1 (de) 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Country Status (8)

Country Link
US (2) US8168194B2 (de)
EP (1) EP1893650B1 (de)
CN (1) CN101146827A (de)
AT (1) ATE471947T1 (de)
CA (1) CA2597040A1 (de)
DE (1) DE602006015050D1 (de)
WO (1) WO2006084179A2 (de)
ZA (1) ZA200707138B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG153796A1 (en) * 2004-06-08 2009-07-29 Novartis Vaccines & Diagnostic Fusion proteins comprising cd4 minimal modules and methods of use thereof
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
US8288345B2 (en) 2007-03-02 2012-10-16 Nono, Inc. Treating stroke and other diseases without inhibiting N-type calcium channels
EP2706356A1 (de) * 2012-09-06 2014-03-12 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Identifizierung HIV-neutralisierender Antikörper
CN111303243B (zh) * 2020-02-25 2021-07-27 徐州医科大学 治疗缺血性脑损伤的小肽tat-akpd及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) * 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
DK0699077T3 (da) * 1993-05-07 2002-01-21 Bio Merieux Inc Immunogele HIV-komplekser
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
FR2799974B1 (fr) 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
CA2458995C (en) 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
BR0308896A (pt) * 2002-05-07 2007-01-09 Chiron Corp complexos e hìbridos envelope do hiv-cd4
GB0218817D0 (en) 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
SG153796A1 (en) * 2004-06-08 2009-07-29 Novartis Vaccines & Diagnostic Fusion proteins comprising cd4 minimal modules and methods of use thereof
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Also Published As

Publication number Publication date
US8637044B2 (en) 2014-01-28
EP1893650A2 (de) 2008-03-05
US20080317779A1 (en) 2008-12-25
CN101146827A (zh) 2008-03-19
WO2006084179A2 (en) 2006-08-10
CA2597040A1 (en) 2006-08-10
US20120183557A1 (en) 2012-07-19
US8168194B2 (en) 2012-05-01
ZA200707138B (en) 2008-11-26
EP1893650B1 (de) 2010-06-23
WO2006084179A3 (en) 2006-12-14
ATE471947T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
TW200738711A (en) Chemical compounds
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
MX2007001958A (es) Compuestos quimicos.
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
NO20082531L (no) Neuropilinantagonister
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
DK1809661T3 (da) Humant interferon-beta-mutein
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
EA200701825A1 (ru) Вакцины против хламидиоза
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
NO20072733L (no) Doseformer
EP1983002A3 (de) Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2009090651A3 (en) Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
DE602006015050D1 (de) Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
ATE479693T1 (de) Phosphoindole als hiv-inhibitoren
WO2008125589A3 (de) Tris(heterocyclyl)-metallkomplexe als bleichkatalysatoren
ATE459375T1 (de) Copolymere auf basis von polyalkylenoxid- modifizierten n-vinyllactam-copolymeren
SG153796A1 (en) Fusion proteins comprising cd4 minimal modules and methods of use thereof
MX2010010393A (es) Uso de la catepsina c.
ATE483720T1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
EP1975184A3 (de) Serin- oder Threonin-Phosphorylationsorte
WO2009099601A3 (en) Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
EP1988103A3 (de) Tyrosinphosphorylationsstellen und spezifische Antikörper